Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS-Reference-Cited by-同舟云学术

Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS

Published:2022-09-27 Issue:10 Volume:1 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Sasaki Koji¹,Jabbour Elias¹,Montalban-Bravo Guillermo¹,Darbaniyan Faezeh²,Do Kim-Anh²,Class Caleb²,Short Nicholas J.¹,Kanagal-Shamana Rashmi³,Kadia Tapan¹,Borthakur Gautam¹,Pemmaraju Naveen¹,Cortes Jorge⁴,Ravandi Farhad¹,Alvarado Yesid¹,Chien Kelly¹,Komrokji Rami⁵,Sekeres Mikkael A.⁶,Steensma David P.⁷,DeZern Amy⁸,Roboz Gail⁹,Soltysiak Kelly¹,Yang Hui¹,Kantarjian Hagop M.¹,Garcia-Manero Guillermo¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston

3. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston

4. Georgia Cancer Center, Augusta

5. Moffitt Cancer Center, Tampa, FL

6. Division of Hematology, Sylvester Cancer Center, University of Miami, Miami

7. Dana-Farber Cancer Institute, Boston

8. Johns Hopkins University, Baltimore

9. Weill Cornell Medical College, New York

Publisher

Massachusetts Medical Society

Reference23 articles.

1. Myelodysplastic Syndromes

2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

3. Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

4. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management

5. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in Lower-Risk MDS;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

3. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome;Current Treatment Options in Oncology;2024-05-30

4. Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms;Cancers;2024-04-19

5. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities;Current Hematologic Malignancy Reports;2024-04-18